CLEMENT Capecitabine-radiosensitizing Lutetium-177 octreotate endoradiotherapy management of endocrine neurogenic tumours Response and Toxicity Assessment

Trial Profile

CLEMENT Capecitabine-radiosensitizing Lutetium-177 octreotate endoradiotherapy management of endocrine neurogenic tumours Response and Toxicity Assessment

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jun 2016

At a glance

  • Drugs Capecitabine (Primary) ; Octreotate-Lu-177-DOTA-Tyr-3 (Primary) ; Temozolomide (Primary)
  • Indications Neuroendocrine tumours
  • Focus Therapeutic Use
  • Acronyms CLEMENT
  • Most Recent Events

    • 08 Jun 2016 Status changed from recruiting to completed.
    • 28 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top